A pilot clinical study on the Traditional Korean Medicine treatment of Amyotrophic lateral sclerosis

근위축성 측삭경화증에 대한 한방 치료의 임상선행연구

  • Kim, Sung-Chul (Dept. of Acupuncture & Moxibustion, Gwang-Ju Oriental Medical Hospital, Wonkwang University) ;
  • Na, Won-Min (Dept. of Acupuncture & Moxibustion, Gwang-Ju Oriental Medical Hospital, Wonkwang University) ;
  • Lim, Na-Ra (Dept. of Acupuncture & Moxibustion, Gwang-Ju Oriental Medical Hospital, Wonkwang University) ;
  • Lee, Do-Sang (Dept. of Acupuncture & Moxibustion, Gwang-Ju Oriental Medical Hospital, Wonkwang University) ;
  • Jang, Eun-Ha (Dept. of Acupuncture & Moxibustion, Gwang-Ju Oriental Medical Hospital, Wonkwang University) ;
  • Song, Bong-Keun (Dept. of Internal Medicine, Gwang-Ju Oriental Medical Hospital, Wonkwang University)
  • 김성철 (원광대학교 광주 한방병원 침구과) ;
  • 나원민 (원광대학교 광주 한방병원 침구과) ;
  • 임나라 (원광대학교 광주 한방병원 침구과) ;
  • 이도상 (원광대학교 광주 한방병원 침구과) ;
  • 장은하 (원광대학교 광주 한방병원 침구과) ;
  • 송봉근 (원광대학교 광주 한방병원 6내과)
  • Published : 2009.03.30


Objectives : This study was to investigate the effect of Oriental medical treatment on ALS. Methods : We investigated 12 ALS patients which were admitted to Gwang-Ju O.M. hospital from Oct. 14, 2008 to Nov. 14, 2008. All patients were treated by SAAM-acupuncture, herb medication, Bee venom Pharmacopuncture therapy, Needle-embedding therapy, etc. We evaluated patients using the Amyotrophic lateral sclerosis Functional Rating Scale-Revised(ALSFRS-R), Medical Research Council (MRC) Scale. Results : After 30 days, mean ALSFRS-R score of patients was improved from $28.42{\pm}7.83$ to $29.08{\pm}7.99$, and mean MRC Scale of patients was improved from $24.79{\pm}8.37$ to $25.34{\pm}8.45$. But in both cases, the variation was not statistically significant. After 30 days, mean ALSFRS-R score and mean MRC Scale of patients was more improved in subjects with bulbar-onset, onset age: 51-60yrs., disease duration: 24-48mo. And the results showed partially significant difference. Conclusions : We think that the results of this case be a pilot study that proves the effect of Oriental Medical treatment on ALS.


  1. Williams DB, Windebank AJ. Motor neuron disease(amyotrophic lateral sclerosis). Mayo Clin Proc 1991;66:54-82
  2. Caroscio JT, Mulvihill MN, Sterling R, et al. Amyotrophic lateral sclerosis its natural history. Neurol Clin. 1987;5:1-9
  3. Kim SH. Diagnosis and therapeutic strategies of amyotrophic lateral sclerosis. Hanyang medical reviews. 2006;26(1):44-51
  4. Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis. A population based study in Ireland, 1996-2000. Journal of Neurology. 2003;250:473-9
  5. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425-31
  6. Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-9
  7. de Carvalho M, Costa J, Swash M. Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements. Amyotrophic Lateral Scler Other Motor Neuron Disord. 2005;6:202-12
  8. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13-21
  9. Mendell JR, Moxley RT, Grigs RC; et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989;320:1592-1597
  10. Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. Philadelphia: F. A. Davis Company. 1998:3-33, 151-163
  11. Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol. 2001;248:612-6
  12. Forbes RB, Colville S, Cran GW, Swingler RJ. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neuron disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2004;75:1753-5
  13. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis:a populationbased study. Neurology. 2003;60:813-9
  14. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amytorophic lateral sclerosis. A study of its presentation and prognosis. J Neuro.l 1985;232:295-300
  15. Rosen AD. Amyotrophic lateral sclerosis: clinical features and prognosis. Arch Neurol (Chicago). 1978;35:638-42
  16. Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol. 1991;48(6):589-93
  17. Brooks BR. What are the implications of early diagnosis? Maintaining optimal health as long as possible. Neurology. 1999;53(Suppl):S43-S45
  18. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a populationbased registry. Neuroepidemiology. 2005;25:114-9
  19. Jessica Mandrioli, Pietro Faglioni. Paolo Nichelli, Patrizia Sola. Amyotrophic lateral sclerosis: Prognostic indicators of survival. Amyotrophic Lateral Sclerosis. 2006;7(4):217-26
  20. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62
  21. Weiss JH, Hartley DM, Koh J, Choi DW. The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. Science. 1990;247:1474-7
  22. Drachman DB, Kunci RW. Amyotrophic lateral sclerosis: an unconventional autoimmune disease Ann Neurol. 1989;26:269-274
  23. Chio A, Mora G, Leone H, et al. Early symptoms progression rate is related to ALS outcome. A prospective population-based study. Neurology. 2002;59:99-103
  24. Turner MR, Bakker M, Sham P, Shaw CE et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. ALS and other motor neuron disorders. 2002;3:15-21
  25. Zoccolella S, Beghi E, Palagano G, Fraddosio A, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. European Journal of Neurology. 2007;14(3):262-8
  26. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole. Neurology. 1997;49:657-9
  27. Sung JJ, Park KH, Kim SH. Clinical scales for Amyotrophic Lateral Sclerosis. J Korean Neurol Assoc. 2005;23(2):88-99
  28. Kim HY. Korean version of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised: A Pilot Study on the Reliability and Validity. J Korean Neurol Assoc. 2007;25(2):149-154
  29. Aitkens S, Lord J, Bernauer E, Fowler WM Jr, Lieberman JS, Berck P. Relationship of manual muscle testing to objective strength measurements. Muscle Nerve. 1989;12(3):173-7
  30. Medical Research Council. Aids to the Examination of the Peripheral Nervous System. London, England: HMSO. 1976:1-2
  31. Kim DH. Illustrations Kyokam Sa-am Do-in Acupucture. Busan: Sogang. 2002:475-480
  32. Jeremy Ross, Dan Bensky. Acupuncture Point Combinations. Churchill Livingstone. 2004:75-99
  33. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 1996;53:141-7
  34. Lee KW. Textbookof Neurology. Seoul: EPUBLIC. 2005
  35. Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993;118:48-55
  36. Park SH, Myung HJ. A Clinical Study on Amyotrophic Lateral Sclerosis. J Korean Neurol Assoc. 1986;4(2):200-8
  37. Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci. 1997;152:10-17
  38. Kim SH, Jung SJ, Park KS, Kim MH, Kim J, Kim HJ, Lee KW. Effects of the Immunoglobulins of Amyotrophic Lateral Sclerosis on Intracellular Calcium in PC12 Cells. J Korean Neurol Assoc. 2000;18(6):728-34
  39. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265-7
  40. Yun-TaoMa, Mila Ma, Zang Hee Cho. Biomedical Acupuncture for Pain Management, Churchill Livingstone. 2005:12-13

Cited by

  1. A Literature Review of Korean Medical Studies of Amyotrophic Lateral Sclerosis (ALS) vol.32, pp.4, 2015,
  2. Why do a pilot study? vol.12, pp.3, 2009,
  3. The follow-up study on patients of Amyotrophic lateral sclerosis after 1 year vol.13, pp.1, 2010,
  4. A case report on the use of processed extract and Korean medical treatment for a patient with Amyotrophic Lateral Sclerosis(ALS) vol.33, pp.2, 2016,
  5. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial vol.19, pp.1, 2018,